# EDGAR Filing Document

**Accession Number:** 0001638833
**File Stem:** 0001638833-25-000124
**Filing Date:** 2025-7
**Character Count:** 4620
**Document Hash:** 2d8caf1397ddb8e2fa299ba3fc38fa4e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001638833-25-000124.hdr.sgml**: 20250922

**ACCESSION NUMBER**: 0001638833-25-000124

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250717

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Surgery Partners, Inc.
- **CENTRAL INDEX KEY:** 0001638833
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 473620923
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 310 SEVEN SPRINGS WAY
- **STREET 2:** SUITE 500
- **CITY:** BRENTWOOD
- **STATE:** TN
- **ZIP:** 37027
- **BUSINESS PHONE:** 615-234-5900

**MAIL ADDRESS:**
- **STREET 1:** 310 SEVEN SPRINGS WAY
- **STREET 2:** SUITE 500
- **CITY:** BRENTWOOD
- **STATE:** TN
- **ZIP:** 37027

![splogo.jpg](splogo.jpg)

July 17, 2025

**VIA EDGAR**

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Industrial Applications and Services

**Re: Surgery Partners, Inc.** 

**Form 10-K for the Year Ended December 31, 2024**

**File No. 001-37576**

Ladies and Gentlemen,

On behalf of Surgery Partners, Inc. (the "Company," "we," or "our"), set forth below are the Company's responses to the comments of the staff (the "Staff") of the Securities and Exchange Commission (the "SEC") within the letter dated July 10, 2025, relating to the Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 7, 2025 (the "2024 Form 10-K").

In this letter, we have recited the comments from the Staff in italicized type and have followed each comment with the Company's response in ordinary type.

<u>Form 10-K for Fiscal Year Ended December 31, 2024</u>

*<u>9. Income Taxes, page F-26</u>*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*1.We note your response to comment 2. With reference to your consolidated statements of operations, please help us better understand how you determined that you were in a cumulative 3-year pre-tax income position as of December 31, 2023 but a pre-tax loss position as of December 31, 2024. Also confirm that you will provide expanded disclosures to communicate to investors the facts and circumstances for the periods presented that support your accounting in future filings.*

The Company respectfully acknowledges the Staff's comment and, in response to the Staff's comment, provides the table below outlining our calculation of the cumulative 3-year pre-tax income position of $14.6 million as of December 31, 2023 (dollars in millions):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **2021** | **2022** | **2023** | **Total** |
| Income before income taxes | $81.2 | $110.3 | $135.0 | $326.5 |
| Less: Net income attributable to non-controlling interests | (141.6) | (141.6) | (147.2) | (430.4) |
| Other comprehensive income (loss) | 29.5 | 107.7 | (18.7) | 118.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $(30.9) | $76.4 | $(30.9) | $14.6 |

---

The table below outlines our calculation of the cumulative 3-year pre-tax loss position of $40.7 million as of December 31, 2024 (dollars in millions):

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **2022** | **2023** | **2024** | **Total** |
| Income before income taxes | $110.3 | $135.0 | $147.1 | $392.4 |
| Less: Net income attributable to non-controlling interests&nbsp;&nbsp;&nbsp;&nbsp; | (141.6) | (147.2) | (180.6) | (469.4) |
| Other comprehensive income (loss)&nbsp;&nbsp;&nbsp;&nbsp; | 107.7 | (18.7) | (52.7) | 36.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $76.4 | $(30.9) | $(86.2) | $(40.7) |

---

The Company confirms to the SEC that it will provide expanded disclosures to communicate to investors the facts and circumstances for the periods presented to support our accounting in future filings.

Please direct any questions or further comments you may have regarding the 2024 Form 10-K or this response letter to the undersigned at 615-234-5900.

---

| | |
|:---|:---|
| **SURGERY PARTNERS, INC.** | **SURGERY PARTNERS, INC.** |
| By: | /s/ David T. Doherty |
|  | David T. Doherty |
|  | Executive Vice President, Chief Financial Officer |

---

cc: &nbsp;&nbsp;&nbsp;&nbsp;Eric Evans, Chief Executive Officer

&nbsp;&nbsp;&nbsp;&nbsp;Jennifer Baldock, Executive Vice President, Chief Administrative & Development Officer

&nbsp;&nbsp;&nbsp;&nbsp;Neil Zieselman, Senior Vice President, Corporate Finance & Controller

<br>